Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors
Immune checkpoint inhibitors have revolutionized cancer management. Some patients with gastrointestinal (GI) tract malignancy have experienced remarkable results. Here, in our review, we discuss predictive/prognostic GI tumor biomarkers that appear to correlate with benefits with this strategy. Rema...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/19/4804 |
| _version_ | 1797480203506679808 |
|---|---|
| author | Jane E. Rogers Kohei Yamashita Matheus Sewastjanow Silva Jaffer A. Ajani |
| author_facet | Jane E. Rogers Kohei Yamashita Matheus Sewastjanow Silva Jaffer A. Ajani |
| author_sort | Jane E. Rogers |
| collection | DOAJ |
| description | Immune checkpoint inhibitors have revolutionized cancer management. Some patients with gastrointestinal (GI) tract malignancy have experienced remarkable results. Here, in our review, we discuss predictive/prognostic GI tumor biomarkers that appear to correlate with benefits with this strategy. Remarkable progress has been made in certain subsets of patients including the potential for solid tumor patients to avoid local therapies such as radiation and/or surgery (organ preservation), which come with acute and chronic risks that have historically been the only curable strategies for these GI tumors. These results provide new and exciting strategies for solid tumor management. Unfortunately, immune checkpoint inhibitors can correlate with biomarkers, but benefits occur in a small subset of patients with GI malignancies. Most frequently, immune checkpoint inhibitors fail to induce response in GI malignancies due to the “cold” tumor microenvironment that protects cancer. Translational strategies are needed to develop effective combination strategies and novel biomarkers to overcome the intrinsic resistance. |
| first_indexed | 2024-03-09T21:56:42Z |
| format | Article |
| id | doaj.art-63155c9f00324eccb4fcaed90657a906 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T21:56:42Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-63155c9f00324eccb4fcaed90657a9062023-11-23T19:56:51ZengMDPI AGCancers2072-66942022-09-011419480410.3390/cancers14194804Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal TumorsJane E. Rogers0Kohei Yamashita1Matheus Sewastjanow Silva2Jaffer A. Ajani3U.T. M.D. Anderson Cancer Center Pharmacy Clinical Programs, Houston, TX 77030, USAU.T. M.D. Anderson Cancer Center Department of Gastrointestinal Medical Oncology, Houston, TX 77030, USAU.T. M.D. Anderson Cancer Center Department of Gastrointestinal Medical Oncology, Houston, TX 77030, USAU.T. M.D. Anderson Cancer Center Department of Gastrointestinal Medical Oncology, Houston, TX 77030, USAImmune checkpoint inhibitors have revolutionized cancer management. Some patients with gastrointestinal (GI) tract malignancy have experienced remarkable results. Here, in our review, we discuss predictive/prognostic GI tumor biomarkers that appear to correlate with benefits with this strategy. Remarkable progress has been made in certain subsets of patients including the potential for solid tumor patients to avoid local therapies such as radiation and/or surgery (organ preservation), which come with acute and chronic risks that have historically been the only curable strategies for these GI tumors. These results provide new and exciting strategies for solid tumor management. Unfortunately, immune checkpoint inhibitors can correlate with biomarkers, but benefits occur in a small subset of patients with GI malignancies. Most frequently, immune checkpoint inhibitors fail to induce response in GI malignancies due to the “cold” tumor microenvironment that protects cancer. Translational strategies are needed to develop effective combination strategies and novel biomarkers to overcome the intrinsic resistance.https://www.mdpi.com/2072-6694/14/19/4804gastrointestinal neoplasmsimmune checkpoint inhibitormicrosatellite-instability-high/deficient mismatch repairprogrammed-death-1programmed death-ligand-1 |
| spellingShingle | Jane E. Rogers Kohei Yamashita Matheus Sewastjanow Silva Jaffer A. Ajani Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors Cancers gastrointestinal neoplasms immune checkpoint inhibitor microsatellite-instability-high/deficient mismatch repair programmed-death-1 programmed death-ligand-1 |
| title | Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors |
| title_full | Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors |
| title_fullStr | Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors |
| title_full_unstemmed | Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors |
| title_short | Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors |
| title_sort | current immune checkpoint inhibitor genetic biomarker exploration in gastrointestinal tumors |
| topic | gastrointestinal neoplasms immune checkpoint inhibitor microsatellite-instability-high/deficient mismatch repair programmed-death-1 programmed death-ligand-1 |
| url | https://www.mdpi.com/2072-6694/14/19/4804 |
| work_keys_str_mv | AT janeerogers currentimmunecheckpointinhibitorgeneticbiomarkerexplorationingastrointestinaltumors AT koheiyamashita currentimmunecheckpointinhibitorgeneticbiomarkerexplorationingastrointestinaltumors AT matheussewastjanowsilva currentimmunecheckpointinhibitorgeneticbiomarkerexplorationingastrointestinaltumors AT jafferaajani currentimmunecheckpointinhibitorgeneticbiomarkerexplorationingastrointestinaltumors |